| Organ-specific manifestations of COVID-19 infection M Gavriatopoulou, E Korompoki, D Fotiou, I Ntanasis-Stathopoulos, ... Clinical and experimental medicine 20, 493-506, 2020 | 522 | 2020 |
| Emerging treatment strategies for COVID-19 infection M Gavriatopoulou, I Ntanasis-Stathopoulos, E Korompoki, D Fotiou, ... Clinical and experimental medicine 21, 167-179, 2021 | 354 | 2021 |
| Epidemiology and organ specific sequelae of post-acute COVID19: a narrative review E Korompoki, M Gavriatopoulou, RS Hicklen, I Ntanasis-Stathopoulos, ... Journal of Infection 83 (1), 1-16, 2021 | 173 | 2021 |
| Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose E Terpos, IP Trougakos, M Gavriatopoulou, I Papassotiriou, AD Sklirou, ... Blood, The Journal of the American Society of Hematology 137 (26), 3674-3676, 2021 | 145 | 2021 |
| The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment E Terpos, M Gavriatopoulou, I Ntanasis-Stathopoulos, A Briasoulis, ... Blood Cancer Journal 11 (8), 138, 2021 | 122 | 2021 |
| Cardiac and renal complications of carfilzomib in patients with multiple myeloma MA Dimopoulos, M Roussou, M Gavriatopoulou, E Psimenou, D Ziogas, ... Blood advances 1 (7), 449-454, 2017 | 100 | 2017 |
| Multiple myeloma and thrombosis: prophylaxis and risk prediction tools D Fotiou, M Gavriatopoulou, E Terpos Cancers 12 (1), 191, 2020 | 59 | 2020 |
| Renal outcomes in patients with AL amyloidosis: prognostic factors, renal response and the impact of therapy E Kastritis, M Gavriatopoulou, M Roussou, M Migkou, D Fotiou, DC Ziogas, ... American journal of hematology 92 (7), 632-639, 2017 | 59 | 2017 |
| Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis E Kastritis, I Papassotiriou, G Merlini, P Milani, E Terpos, M Basset, ... Blood, The Journal of the American Society of Hematology 131 (14), 1568-1575, 2018 | 58 | 2018 |
| The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents M Gavriatopoulou, E Kastritis, I Ntanasis-Stathopoulos, D Fotiou, ... Blood, The Journal of the American Society of Hematology 131 (4), 464-467, 2018 | 56 | 2018 |
| Late‐onset hematological complications post COVID‐19: An emerging medical problem for the hematologist E Korompoki, M Gavriatopoulou, D Fotiou, I Ntanasis‐Stathopoulos, ... American Journal of Hematology 97 (1), 119-128, 2022 | 54 | 2022 |
| Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis E Kastritis, IV Kostopoulos, E Terpos, B Paiva, D Fotiou, M Gavriatopoulou, ... Blood cancer journal 8 (5), 46, 2018 | 49 | 2018 |
| Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit MA Dimopoulos, M Roussou, M Gavriatopoulou, D Fotiou, DC Ziogas, ... Blood Cancer Journal 7 (6), e571-e571, 2017 | 48 | 2017 |
| Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone E Kastritis, I Dialoupi, M Gavriatopoulou, M Roussou, N Kanellias, ... Blood advances 3 (20), 3002-3009, 2019 | 47 | 2019 |
| Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies T Bagratuni, I Ntanasis-Stathopoulos, M Gavriatopoulou, ... Leukemia 32 (12), 2617-2625, 2018 | 46 | 2018 |
| Poor neutralizing antibody responses in 132 patients with CLL, NHL and HL after vaccination against SARS-CoV-2: a prospective study E Terpos, M Gavriatopoulou, D Fotiou, C Giatra, I Asimakopoulos, ... Cancers 13 (17), 4480, 2021 | 45 | 2021 |
| Systemic AL amyloidosis: current approaches to diagnosis and management D Fotiou, MA Dimopoulos, E Kastritis Hemasphere 4 (4), e454, 2020 | 45 | 2020 |
| Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib E Kastritis, M Gavriatopoulou, M Roussou, D Fotiou, DC Ziogas, M Migkou, ... Blood Cancer Journal 7 (6), e570-e570, 2017 | 44 | 2017 |
| Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study M Gavriatopoulou, E Terpos, I Ntanasis-Stathopoulos, A Briasoulis, ... Blood Advances 5 (21), 4398-4405, 2021 | 43 | 2021 |
| Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome M Jalink, S Berentsen, JJ Castillo, SP Treon, M Cruijsen, B Fattizzo, ... Blood, The Journal of the American Society of Hematology 138 (20), 2002-2005, 2021 | 40 | 2021 |
